ADVL 1711: A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors

Grant

Date/time Interval

  • December 13, 2017 - December 12, 2022
  • Total Award Amount

  • 54500.00
  • Direct Costs

  • 40073.00
  • Sponsor Award Id

  • Contributor

  • Ana Galtarossa Xavier   Investigator  
  • Elizabeth Alva   Investigator  
  • Emily Johnston   Investigator  
  • Gregory Friedman M.D.   Principal Investigator  
  • Jamie Aye   Investigator  
  • Kimberly Whelan M.D.   Investigator  
  • Laura Metrock   Investigator  
  • Matthew Kutny M.D.   Investigator  
  • Wayne Liang   Investigator